MIB-1 labelling index is an independent prognostic marker in primary breast cancer

被引:83
作者
Jansen, RLH
Hupperets, PSGJ
Arends, JW
Joosten-Achjanie, SR
Volovics, A
Schouten, HC
Hillen, HFP
机构
[1] Univ Hosp Maastricht, Div Hematol Oncol, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Pathol, NL-6202 AZ Maastricht, Netherlands
[3] Univ Maastricht, Dept Methodol & Stat, Maastricht, Netherlands
关键词
MIB-1; S-phase fraction; prognosis; breast cancer;
D O I
10.1038/bjc.1998.515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proliferative activity of a tumour is considered to be an important prognostic factor in primary breast cancer. We have investigated the prognostic value of the MIB-1 labelling index in 341 patients with primary breast cancer and compared the results with the S-phase fraction in 220 patients of the same cohort. All patients were treated in one hospital and had a median follow-up of 128 months. No correlation between MIB-1 labelling and S-phase fraction could be demonstrated. MIB-1 had prognostic value for disease-free survival in the whole group of patients (P < 0.001) and in the node-negative subgroup (P < 0.001). In multivariate analysis. MIB-1 was an independent prognostic factor (P = 0.004) besides axillary lymph node status (P = 0.001). In univariate analysis high S-phase fraction was associated with decreased overall survival (P = 0.04); however, not in multivariate analysis. Moreover, S-phase fraction had a borderline prognostic significance for post-relapse survival in multivariate analysis (P = 0.08). Thus, in conclusion, the growth fraction of a tumour as determined by the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer.
引用
收藏
页码:460 / 465
页数:6
相关论文
共 39 条
[31]   ANTIGEN RETRIEVAL IN FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUES - AN ENHANCEMENT METHOD FOR IMMUNOHISTOCHEMICAL STAINING BASED ON MICROWAVE-OVEN HEATING OF TISSUE-SECTIONS [J].
SHI, SR ;
KEY, ME ;
KALRA, KL .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1991, 39 (06) :741-748
[32]   BIOLOGIC AND CLINICOPATHOLOGICAL FACTORS AS INDICATORS OF SPECIFIC RELAPSE TYPES IN NODE-NEGATIVE BREAST-CANCER [J].
SILVESTRINI, R ;
DAIDONE, MG ;
LUISI, A ;
BORACCHI, P ;
MEZZETTI, M ;
DIFRONZO, G ;
ANDREOLA, S ;
SALVADORI, B ;
VERONESI, U .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :697-704
[33]   CELL-KINETICS - PROGNOSTIC AND THERAPEUTIC IMPLICATIONS IN HUMAN TUMORS [J].
SILVESTRINI, R .
CELL PROLIFERATION, 1994, 27 (10) :579-596
[34]   REPRODUCIBILITY OF MITOSIS COUNTING IN 2,469 BREAST-CANCER SPECIMENS - RESULTS FROM THE MULTICENTER MORPHOMETRIC MAMMARY-CARCINOMA PROJECT [J].
VANDIEST, PJ ;
BAAK, JPA ;
MATZECOK, P ;
WISSEBREKELMANS, ECM ;
VANGALEN, CM ;
KURVER, PHJ ;
BELLOT, SM ;
FIJNHEER, J ;
VANGORP, LHM ;
KWEE, WS ;
LOS, J ;
PETERSE, JL ;
RUITENBERG, HM ;
SCHAPERS, RFM ;
SCHIPPER, MEI ;
SOMSEN, JG ;
WILLIG, AWPM ;
ARIENS, AT .
HUMAN PATHOLOGY, 1992, 23 (06) :603-607
[35]  
VERONESE SM, 1993, CANCER, V71, P3926, DOI 10.1002/1097-0142(19930615)71:12<3926::AID-CNCR2820711221>3.0.CO
[36]  
2-2
[37]  
VERONESE SM, 1996, ANTICANCER RES, V16, P2717
[38]  
VINDELOV L, 1984, CYTOMETRY, V5, P408
[39]   IMMUNOHISTOCHEMICAL EVALUATION OF GROWTH FRACTIONS IN HUMAN BREAST CANCERS USING MONOCLONAL-ANTIBODY KI-67 [J].
WEIKEL, W ;
BECK, T ;
MITZE, M ;
KNAPSTEIN, PG .
BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (03) :149-154